4-Phenoxybutoxy-substituted heterocycles - A structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3

European Journal of Medicinal Chemistry

Volumn 44, Issue 5, 2009, Pages 1838-1852

  Bodendiek, Silke B ^a   Mahieux, Cédrick ^a   Hänsel, Wolfram ^b   Wulff, Heike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Immunosuppression; Kv1.3; PAP 1; Voltage gated potassium channel

Indexed keywords

1 (4 PHENOXYBUTOXY)ANTHRAQUINONE; 1 (4 PHENOXYBUTOXY)NAPHTHALENE; 1,2 DIHYDRO N METHYL 4 (4 PHENOXYBUTOXY)QUINOLIN 2 ONE; 2 METHYL 6,7 METHYLENEDIOXY 5 (4 PHENOXYBUTOXY) 4H [1]BENZOPYRAN 4 ONE; 2,6 DIHYDRO 8 METHYL 5 (4 PHENOXYBUTOXY)PYRANO[3,2 G][1]BENZOPYRAN 2,6 DIONE; 3 (4 PHENOXYBUTOXY) 2 PHENYL 4H[1]BENZOPYRAN 4 ONE; 4 (4 PHENOXYBUTOXY) 2H[1]BENZOPYRAN 2 ONE; 4 (4 PHENOXYBUTOXY) 5H FURO[3,2 G][1]BENZOPYRAN 5 ONE; 4 (4 PHENOXYBUTOXY) 7H FURO[3,2 G]CHROMENE 7 THIONE; 4 (4 PHENOXYBUTOXY)BENZOFURAN; 4 (4 PHENOXYBUTOXY)FURO[2,3 B]QUINOLINE; 4 (4 PHENOXYBUTOXY)QUINAZOLINE; 4 (4 PHENOXYBUTOXY)QUINOLINE; 4 HYDROXY 6,7 DIMETHOXYFURO[2,3 B]QUINOLINE; 5 (4 PHENOXYBUTOXY) 2H[1]BENZOPYRAN 2 ONE; 5 (4 PHENOXYBUTOXY)ISOQUINOLINE; 5 HYDROXY 2 METHYL 6,7 METHYLENDIOXY 4H [1]BENZOPYRAN 4 ONE; 5 METHOXY 4 METHYL 8 (4 PHENOXYBUTOXY)PSORALEN; 5,8 DIMETHOXY 4 (4 PHENOXYBUTOXY)PSORALEN; 6,7 DIMETHOXY 4 (4 PHENOXYBUTOXY)FURO[2,3 B]QUINOLINE; 7 METHYL 4 (4 PHENOXYBUTOXY) 5H FURO[3,2 G][1]BENZOPYRAN 5 ONE; 7,8 DIMETHOXY 4 (4 PHENOXYBUTOXY)FURO[2,3 B]QUINOLINE; 8 (4 PHENOXYBUTOXY)PSORALEN; 9 (4 PHENOXYBUTOXY)PHENANTHRENE; 9 (4 PHENOXYBUTYL)FURO[2,3 B]QUINOLIN 4(9H)ONE; 9 (PHENOXYBUTOXY) 9H DIBENZO[B,E]PYRAN; 9 METHOXY 7 METHYL 4 (4 PHENOXYBUTOXY) 5H FURO[3,2 G][1]BENZOPYRAN 5 ONE; 9,10 DIHYDRO 4 METHOXY N (4 PHENOXYBUTYL)ACRIDIN 9 ONE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; IC 50; PATCH CLAMP; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; WHOLE CELL;

AUTOIMMUNE DISEASES; FICUSIN; HETEROCYCLIC COMPOUNDS; HUMANS; KV1.3 POTASSIUM CHANNEL; LYMPHOCYTES; METHOXSALEN; RUTA; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 62549084277     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.10.033     Document Type: Article

References (45)

1. Chandy K.G., Wulff H., Beeton C., Pennington M., Gutman G.A., and Cahalan M.D. Potassium channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25 (2004) 280-289
2. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111 (2003) 1703-1713
3. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., Kolski-Andreaco A., Wei E., Grino A., Counts D.R., Wang P.H., Leehealey C.J., Andrews B.S., Sankaranarayanan A., Homerick D., Roeck W.W., Tehranzadeh J., Stanhope K.L., Zimin P., Havel P.J., Griffey S., Knaus H.G., Nepom G.T., Gutman G.A., Calabresi P.A., and Chandy K.G. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 17414-17419
4. Rus H., Pardo C.A., Hu L., Darrah E., Cudrici C., Niculescu T., Niculescu F., Mullen K.M., Allie R., Guo L., Wulff H., Beeton C., Judge S.I., Kerr D.A., Knaus H.G., Chandy K.G., and Calabresi P.A. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11094-11099
5. Koo G.C., Blake J.T., Talento A., Nguyen M., Lin S., Sirotina A., Shah K., Mulvany K., Hora Jr. D., Cunningham P., Wunderler D.L., McManus O.B., Slaughter R., Bugianesi R., Felix J., Garcia M., Williamson J., Kaczorowski G., Sigal N.H., Springer M.S., and Feeney W. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158 (1997) 5120-5128
6. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., Khaytin I., Calabresi P.A., Chen C.Y., Gutman G.A., and Chandy K.G. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 67 (2005) 1369-1381
7. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 166 (2001) 936-944
8. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13942-13947
9. Valverde P., Kawai T., and Taubman M.A. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J. Bone Miner. Res. 19 (2004) 155-164
10. Chandy K.G., Wulff H., Beeton C., Calabresi P.A., Gutman G.A., and Pennington M.W. Kv1.3 potassium channel: physiology, pharmacology and therapeutic indications. In: Triggle D.J., Gopalakrishnan M., Rampe D., and Zheng W. (Eds). Voltage-gated Ion Channels as Drug Targets (2006), Wiley-VCH, Weinheim 214-274
11. Wulff H., Beeton C., and Chandy K.G. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Dev. 6 (2003) 640-647
12. Bohuslavizki K.H., Koppenhofer E., Hansel W., and Moller W.D. A new approach for the treatment of demyelinating diseases?. J. Neuroimmunol. 20 (1988) 251-252
13. Bohuslavizki K.H., Hansel W., Kneip A., Koppenhofer E., Niemoller E., and Sanmann K. Mode of action of psoralens, benzofurans, acridones and coumarins on the ionic currents in intact myelinated nerve fibres and its significance in demyelinating diseases. Gen. Physiol. Biophys. 13 (1994) 309-328
14. + channels: synthesis and photoreactivity. J. Med. Chem. 41 (1998) 4542-4549
15. Bohuslavizki H.K., Hinck-Kneip C., Kneip A., Koppenhofer E., and Reimers A. Reduction of MS-related scotoma by a new class of potassium channel blockers from Ruta graveolens. Neuroophthalmology 13 (1993) 191-198
16. Vennekamp J., Wulff H., Beeton C., Calabresi P.A., Grissmer S., Hansel W., and Chandy K.G. Kv1.3 blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol. Pharmacol. 65 (2004) 1364-1373
17. Schmitz A., Sankaranarayanan A., Azam P., Schmidt-Lassen K., Homerick D., Hansel W., and Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 68 (2005) 1254-1270
18. Pereira L.E., Villinger F., Wulff H., Sankaranarayanan A., Raman G., and Ansari A.A. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp. Biol. Med. (Maywood) 232 (2007) 1338-1354
19. Azam P., Sankaranarayanan A., Homerick D., Griffey S., and Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Invest. Dermatol. 127 (2007) 1419-1429
20. Wulff H., and Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr. Opin. Drug Discov. Dev. 10 (2007) 438-445
21. Ohta T., Mori Y., Noda C., and Aoki T. Furoquinolines. XX. Alkaloids of the leaves of Ruta graveolens and synthesis of dihydrokokusaginine. Chem. Pharm. Bull. 8 (1960) 377-379
22. Butenschon I., Moller K., and Hansel W. Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J. Med. Chem. 44 (2001) 1249-1256
23. Harvey A.J., Baell J.B., Toovey N., Homerick D., and Wulff H. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J. Med. Chem. 49 (2006) 1433-1441
24. Baell J.B., Gable R.W., Harvey A.J., Toovey N., Herzog T., Hansel W., and Wulff H. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J. Med. Chem. 47 (2004) 2326-2336
25. Schmalhofer W.A., Bao J., McManus O.B., Green B., Matyskiela M., Wunderler D., Bugianesi R.M., Felix J.P., Hanner M., Linde-Arias A.-R., Ponte C.G., Velasco L., Koo G., Staruch M.J., Miao S., Parsons W.H., Rupprecht K., Slaughter R.S., Kaczorowski G.J., and Garcia M.L. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry 18 (2002) 7781-7794
26. Felix J.P., Bugianesi R.M., Schmalhofer W.A., Borris R., Goetz M.A., Hensens O.D., Bao J.M., Kayser F., Parsons W.H., Rupprecht K., Garcia M.L., Kaczorowski G.J., and Slaughter R.S. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry 38 (1999) 4922-4930
27. 3CN combination. Synth. Commun. 28 (1998) 2021-2026
28. Yamamoto K., Jikei M., Miyatake K., Katoh J., Nishide H., and Tsuchida E. Sulfide bond formation for the synthesis of poly(thioarylene) through oxidation of sulfur chloride with aromatics. Macromolecules 27 (1994) 4312-4317
29. Lamberton J.A., and Price J.R. Alkaloids of the Australian Rutaceae: Acronychia baueri. IV. Alkaloids present in the leaves. Aust. J. Chem. 6 (1953) 66-77
30. Ishii H. Alkaloids of Rutaceous plants. XIV. Syntheses of some hydrogenated derivatives of skimmianine. Yakugaku Zasshi 81 (1961) 248-253
31. Schonberg A., and Badran N. Khellin from visnagin. J. Am. Chem. Soc. 73 (1951) 2960-2961
32. Ahluwalia V.K., Arora K.K., and Prakash C. Selective Claisen migration in chromones. A convenient synthesis of the linear furanochromones desmethoxyvisnagin, norvisnagin, and visnagin. Gazz. Chim. Ital. 111 (1981) 103-107
33. Dubuffet T., Loutz A., and Lavielle G. An efficient large scale synthesis of coumarins by a dealkylative boron-mediated ring closure of 3-(ortho-methoxyaryl)propenoic esters. Synth. Commun. 29 (1999) 929-936
34. Cerqueira N.M.F.S.A., Oliveira-Campos A.M.F., Coelho P.J., Melo De Carvalho L.H., Samat A., and Guglielmetti R. Synthesis of photochromic dyes based on annulated coumarin systems. Helv. Chim. Acta 85 (2002) 442-450
35. Kneen G., and Maddocks P.J. A convenient synthesis of 4-hydroxybenzo(b)furan, (karanjol). Synth. Commun. 16 (1986) 1635-1640
36. Bonini C., Cristiani G., Funicello M., and Viggiani L. Facile entry to 4- and 5-hydroxybenzofuran and to their amino derivatives. Synth. Commun. 36 (2006) 1983-1990
37. Spath E., and Gruber W. Natural chromones. II. Constitution of visnagin (from Ammi visnaga). Ber. Dtsch. Chem. Ges. 74B (1941) 1492-1500
38. Abdel-Rahman A.-R.H., Keshk E.M., and El-Telbani E.M. Linearly fused furochromones by intramolecular enaminone reactions. Z. Naturforsch., B: Chem. Sci. 57 (2002) 557-562
39. Schonberg A., and Aziz G. Furochromones and coumarins. VI. Demethylation of xantotoxin, khellin and khellol with aniline hydrochloride and magnesium iodide. Am. J. Chem. Soc. 75 (1953) 3265-3266
40. Gammill R.B., and Nash S.A. Oxymetallation of khellin. Solvomercuration, osmylation, and palladium-catalyzed oxidation of the furan ring in khellin. The synthesis of highly oxygenated chromones and 2-substituted furochromones. J. Org. Chem. 51 (1986) 3116-3123
41. Atta S.M.S., Hafez T.S., and Mahran M.R. Organophosphorus chemistry. 25. The utilization of Wittig reagents in lactone ring formation. Application to the synthesis of linear furocoumarins and pyranocoumarins. Phosphorus, Sulfur Silicon Relat. Elem. 80 (1993) 109-116
42. Morel A.F., Larghi E.L., and Selvero M.M. Mild, efficient and selective silver carbonate-mediated O-alkylation of 4-hydroxy-2-quinolones. Synthesis of 2,4-dialkoxyquinolines. Synlett (2005) 2755-2758
43. Bhoga U., Mali R.S., and Adapa S.R. New synthesis of linear furoquinoline alkaloids. Tetrahedron Lett. 45 (2004) 9483-9485
44. Narasimhan N.S., and Mali R.S. Synthetic application of lithiation reactions. VI. New synthesis of linear furoquinoline alkaloids. Tetrahedron 30 (1974) 4153-4157
45. Grundon M.F., and McCorkindale N.J. Synthesis of g-fagarine and dictamnine. Chem. Ind. (London, United Kingdom) (1956) 1091-1092